Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Cajal Neuroscience has raised $96.0M in total funding. The most recent round was Series A. The last funding was announced in November 2022.
Cajal Neuroscience's investors include Lux Capital, Two Sigma Ventures, Bristol-Myers Squibb, Alexandria Venture Investments, Evotec.
Cajal Neuroscience is headquartered in Seattle, United States.
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Cajal Neuroscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cajal Neuroscience — Funding & Investors." VCBacked, November 29, 2022, https://www.vcbacked.co/company/cajal-neuroscience. Accessed August 14, 2026.
VCBacked. (2022). Cajal Neuroscience — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/cajal-neuroscience
{{cite web |title=Cajal Neuroscience — Funding & Investors |url=https://www.vcbacked.co/company/cajal-neuroscience |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated